Title: Storyboards for anti-Proprotein convertase subtilisin kexin 9 (PCSK9) based on Evolocumab, a novel LDL reducing monoclonal antibody 

 

Tools: VMD, Photoshop

Target Audience: Cardiologists (marketing campaign for launching of Evolocumab)

Background: A novel monoclonal antibody therapy targeting proprotein convertase subtilisin kexin 9 to reduce low‐density lipoprotein cholesterol (LDL). PCSK9 is an enzyme that impairs LDL clearance from the plasma by promoting LDL receptor degradation. PCSK9 binds to LDL receptors present on the surface of hepatocytes (liver cells). When PCSK9 binds an LDL receptor, the latter is taken into the cell and degraded. This in turn leaves fewer LDL receptors available on hepatocytes to remove excess LDL from the blood. Amgen and Sanofi/Regeneron have FDA approved PCSK9 therapies

References

Harris LJ, Larson SB, Hasel KW, McPherson A. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry. 1997;36(7):1581-1597. 

Huang S, Henry L, Ho YK, Pownall HJ, Rudenko G. Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor. J Lipid Res. 2010;51(2):297-308. doi:10.1194/jlr.M000422. 

Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53(12):2515-2524. 

Nikolac N. Lipemia: causes, interference mechanisms, detection and management. Biochemia Medica. 2014;24(1):57-67. doi:10.11613/BM.2014.008.

Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res. 2008;49(7):1595-1599. 

 

 

 

 

Get in touch
I would love to collaborate with you, call me or drop me a note and let's find the visual solution to the story you want to tell.
(309) 740-8373 
 
  • LinkedIn - White Circle
  • Vimeo - White Circle
  • Twitter - White Circle

All contents © 2021 by Grace Hsu.

 

anti-PCSK9 storyboard

Page 2 of 4